Table 1.
Category | DNA Vaccines | RNA Vaccines |
---|---|---|
Design | Rapid design with the coding sequence of antigens A single formulation with multiple antigens is possible |
Rapid design with the coding sequence of antigens A single formulation with multiple antigens is possible |
Production | Rapid and reproducible production based on in vitro bacterial culture Large-scale manufacture without inactivation of infectious pathogens or purification of recombinant antigens Antigens with proper folding are produced in vivo |
Rapid and reproducible production based on in vitro transcription Large-scale manufacture with “cell free” process Antigens with proper folding are produced in vivo, with the cytosol as its target, only transiently expressed |
Stability | Depends on the formulation Ease of storage and transportation in most cases |
Depends on the formulation Cold chain transportation is generally required |
Immune responses | Both cellular and humoral immune responses | Both cellular and humoral immune responses without risk of genome integration |